Antibiotic Prescribing in Dentistry: SDCEP Guide & Doses (UK 2026)

SDCEP dose table: acute apical (dentoalveolar) abscess (adults)

Review at around 3 days, keep the course short (usually 3–5 days), and stop once drainage is achieved and the patient is improving. Verify every figure against the current SDCEP Drug Prescribing for Dentistry and BNF (as of June 2026).

Source: SDCEP Drug Prescribing for Dentistry (sdcepdentalprescribing.nhs.scot), Bacterial Infections, Dental abscess, First line antibiotics. The Bacterial Infections section was updated in May 2026, and the guidance was updated on 2 October 2026 to reflect BNF 92 and BNFC 2026–2027.

When antibiotics are and are not indicated (drainage first)

The single most important stewardship message in UK dental prescribing is this: antibiotics do not drain an abscess, and they do not treat irreversible pulpitis. They are not a substitute for definitive local treatment. Treat dental abscesses in the first instance with local measures to achieve drainage and removal of the cause where possible (current SDCEP Drug Prescribing for Dentistry; verify as of June 2026).

Antibiotics are generally NOT indicated for:

• Irreversible pulpitis, acute apical periodontitis, or a localised acute apical (periapical) abscess where drainage can be achieved locally.
• A chronic apical abscess or sinus tract.
• “Just in case” before or after a routine extraction in a healthy patient.
• Routine management of chronic periodontitis.
• Dry socket (alveolar osteitis) without spreading infection.

Antibiotics MAY be indicated, as an adjunct to local measures, when there are:

• Signs of spreading infection — diffuse swelling, cellulitis, trismus, lymph-node involvement, or spread towards the fascial spaces, the eye, the floor of mouth or the neck.
• Signs of systemic involvement — fever, malaise, tachycardia, raised respiratory rate, dehydration.
• An immunocompromised patient, or one in whom infection poses a disproportionate risk.
• A situation where drainage cannot be achieved (for example, the patient cannot tolerate treatment and definitive care must be delayed).

Spreading odontogenic infection (with systemic features)

For spreading infection with systemic features, manage in the community while arranging definitive care or referral — and refer urgently if there are red-flag or systemic features.

Acute periodontal conditions

Systemic antibiotics are not routinely indicated for chronic periodontitis; management is mechanical (debridement) and behavioural, consistent with British Society of Periodontology (BSP) guidance. Antibiotics have a defined, limited role in specific acute presentations:

Combination regimens (for example amoxicillin plus metronidazole) are sometimes described in the literature for specific severe or grade C cases, but this is a specialist decision and not a routine general-practice prescription; align with the current BSP position.

Penicillin-allergy alternatives

A documented penicillin allergy changes the first-line choice. Clarify the nature of the reaction (true allergy versus intolerance) and record it, because it affects both treatment and IE-prophylaxis decisions. Verify each regimen against current SDCEP/BNF (as of June 2026), and check interactions and cautions for every patient — macrolides (clarithromycin) and metronidazole both interact with warfarin and other drugs.

Clarithromycin and clindamycin are SDCEP second-line agents for non-response to first-line or severe spreading infection — they are not the routine penicillin-allergy first choice, which is metronidazole. For interaction checks at the chairside, the Drug Interactions reference and the Antibiotic Guide in the Nosht app give an SDCEP-based starting point — but the current BNF interactions checker remains the authority, and you should always confirm there.

Infective-endocarditis (IE) prophylaxis: the NICE CG64 position

NICE CG64 (Prophylaxis against infective endocarditis, originally 2008; recommendation wording last updated 8 July 2016) states, at recommendation 1.1.3, that antibiotic prophylaxis against infective endocarditis is not recommended routinely for people undergoing dental procedures. The 2016 update added the word “routinely”, which is widely understood to leave room for individualised decisions in a small group at increased risk — but the default position remains no routine prophylaxis. NICE also states (recommendation 1.1.4) that chlorhexidine mouthwash should not be offered as IE prophylaxis. In October 2024, following exceptional surveillance, NICE left the CG64 recommendations unchanged but added a signpost to the SDCEP implementation advice; in December 2024 it further clarified recommendation 1.1.3 for people undergoing dental procedures and its link to that SDCEP advice. Verify against the current NICE guidance, as of June 2026.

To operationalise CG64 in dentistry, SDCEP publishes implementation advice (Antibiotic Prophylaxis Against Infective Endocarditis), which describes a pathway for identifying patients who may merit special consideration and emphasises shared decision-making with the patient and liaison with the patient’s cardiologist or cardiac team. SDCEP published the second edition of this implementation advice in March 2026; confirm the current online version and date.

NICE CG64 (recommendation 1.1.1) identifies these people as at increased risk of infective endocarditis:

• Acquired valvular heart disease with stenosis or regurgitation.
• Valve replacement (prosthetic heart valve).
• Structural congenital heart disease, including surgically corrected or palliated structural conditions — but excluding isolated atrial septal defect, fully repaired ventricular septal defect, fully repaired patent ductus arteriosus, and closure devices judged to be endothelialised.
• Hypertrophic cardiomyopathy.
• Previous infective endocarditis.

SDCEP/ESC pathways further single out a highest-risk subset for whom special consideration is most relevant (prosthetic valve or prosthetic valve-repair material including transcatheter valves; previous IE; specified cyanotic or repaired congenital heart disease). This list determines patient-safety decisions — verify the exact wording and inclusion criteria against current guidance, as of June 2026.

If prophylaxis is decided upon (special-consideration patient, agreed with cardiology)

Verify these regimens against the current SDCEP IE-prophylaxis implementation advice, NICE CG64 and the current BNF/BNFC (as of June 2026) before use.

Duration, review and stewardship principles

• Use the shortest effective course. SDCEP regimens for acute dental infection are short (usually 3–5 days for an abscess; 3 days for necrotising gingivitis), with review at 3 days built in.
• Review and stop early once drainage is achieved and the patient is improving; do not “complete the course” reflexively if the infection source has been definitively treated.
• Definitive treatment is the cure. The antibiotic buys time; the tooth still needs endodontics or extraction.
• Document the indication. Dental prescribing is a recognised contributor to antimicrobial resistance, and stewardship audit increasingly expects a recorded justification for every course.

Who in the team may prescribe or supply (and under what mechanism — prescription, Patient Group Direction, or exemptions) differs between dentists, dental therapists and hygienists and depends on current medicines legislation. Confirm the current position for your role against the GDC scope of practice guidance and the current Human Medicines Regulations.

Documenting the prescribing decision in your notes

A defensible antibiotic entry records why you prescribed, not just what. For each course, your clinical notes should capture:

• The diagnosis or indication, and the specific sign(s) of spreading or systemic infection that justified an antibiotic.
• That local/operative measures were performed or attempted (drainage, extirpation, extraction) — or why they could not be.
• Allergy status checked and recorded, and medical history and interactions reviewed (for example warfarin, statins).
• The drug, dose, frequency and duration, and the review plan.
• Advice given to the patient, including return-if-worse safety-netting.

This is exactly the kind of structured, repeatable entry where a template helps. Nosht provides GDC / CGDent (formerly FGDP(UK))-aligned note templates so the prescribing rationale, allergy check and review plan are prompted as discrete fields rather than left to free text.

Nosht uses optional, clinician-reviewed AI (Anthropic’s Claude Haiku 4.5) in two narrow ways: it can turn your shorthand into structured note fields that you review and confirm line by line, and it offers an advisory “Bulletproof” check that flags where a note may be incomplete. The template core is deterministic, and the AI is never trained on your notes. Unlike ambient or voice-based AI scribes that record and transcribe the consultation, Nosht’s structured-notes workflow does not record audio — you type shorthand; there is no voice capture in this workflow, and you confirm every field yourself. The dose values themselves still come from you and from current SDCEP/BNF, not from the AI, and most templates have no patient-identifier fields (referral letters and leaflet sending excepted); you copy the finished note into your own practice-management system, which remains your system of record.

Pregnancy and medical-history cautions (brief)

Prescribing in pregnancy, breastfeeding, renal or hepatic impairment, and alongside interacting medicines requires individual checking — this is a brief flag, not a complete reference. Always confirm against the current BNF/BNFC and, where relevant, the patient’s GP or specialist.

• Amoxicillin / phenoxymethylpenicillin are generally considered acceptable in pregnancy where indicated (BNF pregnancy guidance — verify).
• Metronidazole — manufacturer/BNF cautions apply (for example avoidance of high-dose regimens; prescriber judgement in pregnancy); avoid alcohol in all patients.
• Clarithromycin — BNF/manufacturer generally advise use only if the benefit outweighs the risk in pregnancy.
• Warfarin and DOACs, statins, methotrexate and others interact with these antibiotics — check before prescribing.

Interaction checks are available in the Drug Interactions reference in the Nosht app, but the current BNF is the authority.

Clinical reference tools

Nosht includes a set of chairside clinical reference tools for subscribed clinicians, including an Antibiotic Guide (an SDCEP-based prescribing reference), a Drug Interactions reference, Paediatric Doses, an LA Dose Reference and RCUK-aligned Emergency Protocols. These are reference aids, not prescribing authority, and they should always be cross-checked against the current BNF/BNFC and SDCEP. They are part of the subscription and are accessed inside the Nosht app.

Free, public tools you can use right now include the BPE calculator, the NHS UDA calculator, the tooth-notation converter and the GDC Scope of Practice Checker.

Sources

• SDCEP Drug Prescribing for Dentistry: Bacterial infections (accessed 11 October 2026)
• BNF: Phenoxymethylpenicillin (accessed 11 October 2026)
• BNF: Amoxicillin (accessed 11 October 2026)
• BNF: Metronidazole (accessed 11 October 2026)
• NICE CG64: Prophylaxis against infective endocarditis (accessed 11 October 2026)
• SDCEP: Antibiotic prophylaxis (accessed 11 October 2026)